INDIANAPOLIS--Earlier this month, Eli Lilly here announced a deal with Tokyo-based Chugai Pharmaceutical in which the American firm will share proprietary combinatorial chemistry expertise in exchange for up-front fees, milestone payments, and royalties on the first two products that reach the market as a result of the collaboration. Among the techniques and technologies that will be shared are some gained as a result of Lilly's 1994 acquisition of Sphinx Pharmaceuticals, which significantly expanded Lilly's competence in combinatorial chemistry.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.